This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Adipokines as Predictors of the Metabolic Syndrome in ALL Survivors

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified November 2007 by Sheba Medical Center.
Recruitment status was:  Not yet recruiting
Information provided by:
Sheba Medical Center Identifier:
First received: November 30, 2007
Last updated: NA
Last verified: November 2007
History: No changes posted

Background: Acute Lymphoblastic Leukemia (ALL) is the most common malignancy in children. It accounts for 25% of all childhood cancers. Peak incidence occurs between 2 to 5 years of age. Modern treatment regimens have improved cure rates from virtually zero (in the 1950's) to current overall survival rates of approximately 80%.The high survival rates have introduced us to novel medical problems as a consequences of the different treatment regimens. No single treatment modality exists today but rather several treatment protocols are accepted worldwide. As such, the population of the childhood ALL survivors differ in their toxic exposure: cranial & spinal radiotherapy, intrathecal and/or systemic chemotherapy and bone marrow transplantation .As the survival rates grow, there are more young adult ALL survivors worldwide susceptible to these late effects of treatment.

Numerous reports have pointed out that this particular group is at increased risk to develop cardiovascular disease (CVD) and diabetes (MS). The metabolic syndrome, i.e hypertension, dyslipidemia, impaired glucose metabolism and obesity, occurs at a younger age than the general population.

Adipocytokines, mediators secreted by adipose tissue, play an important role in the regulation of carbohydrates and lipid metabolism.Changes in serum adipokine levels precede the clinical symptoms.

We aim to identify and assess prevalence of the MS in ALL survivors. We aim to characterize the population at risk to develop DM and CVD prior to overt clinical disease. Characterization will be done by measuring serum adipocytokines and inflammatory cytokine profiles .Biochemical characterization of the group at risk will enable us to intervene in the preventive stage in the future.

Condition Intervention
Leukemia Metabolic Syndrome X Other: sample without DNA

Study Type: Observational
Study Design: Observational Model: Cohort
Official Title: Adipocytokines as Predictors of the Metabolic Syndrome in Survivors of Childhood Acute Lymphoblastic Leukemia

Resource links provided by NLM:

Further study details as provided by Sheba Medical Center:

Biospecimen Retention:   Samples Without DNA
Serum leptin, resistin ,adiponectin ,CRP, PAI ,TNF-α, IL-6 will be taken as part of initial blood test screening in patients following an overnight fast. Adiponectin and leptin levels will be determined by RIA (Linco, St. Charles, MO), Insulin, will be determined by chemiluminescent immunometric method (Immulite 2000, Diagnostic Products Corporation, Los Angeles, CA).

Estimated Enrollment: 150
Study Start Date: January 2008
Estimated Study Completion Date: December 2008
Groups/Cohorts Assigned Interventions
ALL survivors 5 years after completion of treatment, during routine medical follow up
Other: sample without DNA
family history, anthropometric measurements and blood sampling


Ages Eligible for Study:   6 Years to 45 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Hematoncological pediatric clinic

Inclusion Criteria:

  • ALL diagnosis
  • five years after completion of treatment
  • leukemia free during research

Exclusion Criteria:

  • ongoing chemotherapy and radiotherapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00566566

Contact: Bella Bielorai, MD 972-3-5302692

Sponsors and Collaborators
Sheba Medical Center
Principal Investigator: Yael Weintraub, MD Tel Aviv University
  More Information


Responsible Party: Dr. Yael Weintraub, Sheba Medical Cener Identifier: NCT00566566     History of Changes
Other Study ID Numbers: SHEBA-07-4861-YW-CTIL
Study First Received: November 30, 2007
Last Updated: November 30, 2007

Keywords provided by Sheba Medical Center:
inflammatory markers
cardiovascular disease
diabetes mellitus

Additional relevant MeSH terms:
Metabolic Syndrome X
Pathologic Processes
Neoplasms by Histologic Type
Insulin Resistance
Glucose Metabolism Disorders
Metabolic Diseases processed this record on September 20, 2017